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cially influenced by the occurrence of motor complica-
tions.
CONCLUSIONS: Similar to earlier studies (Dodel et al.,
1995), an increase in costs was calculated depending on
HY stage and the occurrence of motor complications.
Compared to the medical costs, the non-medical services
contribute only in a small proportion to the overall direct
costs. The major cost factor is the drug treatment of Par-
kinson’s disease. The greatest proportion of these costs is
for drugs introduced in the last five years.
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OBJECTIVES: To assess the costs of multiple sclerosis (MS)
from a sample of 157 French patients followed during 2
years (1 year retrospectively, 1 year prospectively) and con-
secutively included from June 1995 to December 1996.
Costs included health-care consumption, lost earnings and
payment of short-term disability benefits by Social Security.
METHODS: At the time of inclusion, the costs of MS
were assessed by retrospective interviews covering a one-
year period (health-care costs and sick leaves) or since the
last consequence of MS on work (loss of earnings). The
retrospective data concerning both the health-care con-
sumption and sick leaves were completed with prospec-
tive data collected by means of a questionnaire during the
three-months following inclusion. Loss of earnings was
discounted at 5%. Cost estimates were crossed with med-
ical data at inclusion, and econometric analyses were per-
formed to assess explanatory variables of the health-care
costs.
RESULTS: Baseline statistics were: mean age, 42.9;
women, 66%; secondary progression, 37%; primary pro-
gression, 11%; median EDSS score, 5.25. Average one-
year retrospective health-care costs (N  157) amounted
to US$7,790.38 (/ US$9,713.88), with 75.4% going
towards hospital costs and 24.6% to ambulatory costs.
Main cost items were hospital stay in the neurological
ward (29.4% of the total cost) and physiotherapy
(15.4%). Three-month prospective healthcare costs
(N101) amounted to US$1,813 (/ US$2,056), with
56.5% spent on hospital costs. Physiotherapy and drugs
were the main ambulatory cost items, accounting for
40.0% and 24.6% respectively of the total prospective
ambulatory costs.
CONCLUSION: The econometric analysis showed that the
health-care costs were positively correlated with the num-
ber of years of schooling, the number of relapses, the EDSS
score and the Kurtzke sphincter subscore at inclusion,
negatively correlated with the Kurtzke sight subscore at
inclusion, and were not affected by the form of MS.
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MS affects approximately 85,000 people in the UK, of
which 25% to 40% will be RRMS patients. Treatment
costs fall largely on the NHS, but savings on social and
personal care will accrue if dependency is deferred. Sim-
plistic treatment algorithms based on crude prevalence
data may overestimate the number of patients and cost of
treatment.
OBJECTIVE: Present a treatment algorithm providing a
more realistic estimate of the number of RRMS patients
eligible for therapy, and thereby, an improved estimate of
budget implications of prescribing.
METHODS: Published prevalence data indicate the num-
ber of patients for whom treatment is theoretically eligi-
ble is 25 to 71 per 100,000 population (mid-point 48).
However, using published literature and feedback from
expert clinicians, we show that these numbers can be re-
duced to reflect those patients who will refuse injectable
therapy, are too young (below 18), have not relapsed in
the previous two years or are non-ambulatory.
RESULTS: We present an algorithm based on glatiramer
acetate, given the published evidence of long-term efficacy
and the significantly lower price (almost 30% cheaper
than the beta interferons in the UK). Using published data
to quantify the proportions of ineligible patients, the origi-
nal target population of 48 is reduced to 23. Depending on
the proportion of these patients that receives glatiramer ac-
etate, e.g., 20%, 40%, or 60%, the budget provision per
100,000 population would be £33,250, £59,850, or
£93,100 respectively, based on direct acquisition cost of
therapy alone versus best supportive care alone.
CONCLUSION: The algorithm provides a tool for deter-
mining a more realistic estimate of the RRMS population
eligible for treatment, and the direct costs to the NHS.
Given that NHS and Social Care budgets will increas-
ingly be managed jointly, budgetary impact is mitigated if
wider benefits such as deferred dependency and ability to
continue employment are taken into account.
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OBJECTIVES: The objective of this study was to assess
the potential cost savings associated with a reduction in
the utilization of psychotropic medications in Alzhei-
mer’s Disease (AD) patients receiving rivastigmine and
residing in long-term care facilities.
METHODS: A 26-week, open-label clinical trial assess-
ing the effect of rivastigmine on behavioral problems of
AD was conducted at 29 long-term care facilities in the
United States. Patients were titrated to the best tolerated
dose between 3 and 12 mg/day of rivastigmine. All pa-
tients were at least 50 years of age and diagnosed with
AD. This analysis focused on the cohort of 69 of 173 pa-
tients who completed 26 weeks of rivastigmine therapy
and were receiving antipsychotic medication at some
point during those 26 weeks. This analysis measured the
average daily cost of these drugs (sorted into 5 classes)
over the 26- week period.
RESULTS: There was no appreciable difference over time in
the average daily cost of any class of psychotropic medica-
tions except antipsychotics. The average daily cost of anti-
psychotic medication decreased from $1.57 (SD$4.70) at
day 0 compared to $0.88 (SD$1.93) at day 180.
CONCLUSIONS: This analysis demonstrates decreased
utilization of antipsychotic medications in institutionalized
AD patients receiving rivastigmine. It also suggests that
patients taking rivastigmine may realize cost savings as-
sociated with decreased use of antipsychotic medications.
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OBJECTIVES: To assess the prevalence rate of concomi-
tant drug use and the potential for drug interactions in
Alzheimer’s Disease (AD) patients prescribed donepezil.
METHODS: Outpatient pharmacy claims data from the
Protocare Sciences Proprietary Managed Care database
during the period from October 1, 1998 to December 31,
1998 was reviewed. Donepezil-treated patients were de-
fined as patients having at least one outpatient pharmacy
claim for donepezil. Patients at risk of potential drug-
drug interaction were identified as those patients who
were prescribed at least one drug that has the potential to
interact with donepezil based on published literature in-
cluding the package insert. AD patients with the above
criteria were classified as being at risk for adverse reac-
tions.
RESULTS: Among AD patients using donepezil, 41%
were prescribed at least one medication with the poten-
tial to interact with donepezil.
CONCLUSIONS: Based on this study, forty-one out of
every 100 patients who use donepezil are likely to experi-
ence drug-drug interactions. The risk that this confers
warrants physician attention and policy considerations at
several levels of organization. To avoid adverse clinical
effects and the economic consequences of drug interac-
tions, donepezil should be prescribed with caution, and
alternative medications that do not have a potential for
interaction should be considered.
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OBJECTIVE: Chronic headache is a disease where im-
provement in quality of care is not only beneficial for the
patient but also a mandatory goal. Disease-management
approaches focusing on patient education are means by
which to reduce symptom severity, workplace absentee-
ism and improve health-related quality of life (HRQoL).
METHODS: Non-scientific employees (N  5000) of
Dresden University were screened for migraine and ten-
sion-type headache (TTH) according to International
Headache Society criteria (n  378). Patients were asked
about their HRQoL (MOS Short-Form 36) and about
therapy patterns using non-standardized questions, suc-
cess, satisfaction, and workplace absenteeism both before
and one year (settlement phase) after intervention. Inter-
vention was by basic information material and a volun-
tary two-hour intensive patient education program in ac-
cordance with therapy recommendations. Results were
obtained by means of descriptive statistics and compari-
son of run-in and post-intervention data.
RESULTS: One hundred forty three patients returned the
post-intervention questionnaire. Patient education ses-
sions were attended by 54 patients. Overall, 27.6% were
able to treat their headache more successfully after inter-
vention; 42.3% were still not under GP surveillance. Mi-
graine treatment with triptans was most successful for all
eligible patients. Success rate in ergotamine users was
72.2%. 39.5% of patients changed their medication dur-
ing the settlement phase. Education in combination with
change in medication yielded maximum increase in
HRQoL. Patients with severe initial pain had a signifi-
cant increase in HRQoL scores for three dimensions:
pain (19.7), physical functioning (10.4), and social
functioning (10.5). Direct and indirect workplace ab-
senteeism decreased by 3.14 hours per four-week period,
gaining more than 600 Euros/year/patient (human capital
approach). The benefit of patients switching medication
was 5.26 hours/patient.
CONCLUSION: The study results demonstrate that edu-
cation of patients results in a change of coping strategies,
reduced headache severity, improved HRQoL, increased
satisfaction and restored productivity.
